Four selected reports cover intravenous ipamorelin in bowel-surgery patients and healthy volunteers, plus analytical reports involving nasal exposure. These different purposes and routes do not establish benefit for other proposed uses.1234
Bottom line from this bounded source set
The postoperative-ileus trial found no statistically significant improvement in its key or secondary efficacy analyses. The healthy-volunteer study measured growth hormone responses, which do not establish clinical benefit. The additional urine studies concern detection and receptor binding, not therapeutic benefit.1234
Reviewed study record
Postoperative ileus: a placebo-controlled phase 2 trial
Design
A multicenter blinded randomized placebo-controlled study assessed recovery after bowel resection.1
Population
The trial enrolled 117 adults; 114 were included in its safety and modified intent-to-treat populations.1
Outcomes reported
Time to a tolerated solid meal was not significantly different between groups. Treatment-emergent adverse events occurred in 87.5% with ipamorelin and 94.8% with placebo.1
Limitations
The study was small and included varied underlying conditions. A nonsignificant result does not prove equivalence, and these postoperative findings do not establish safety for other uses or routes.1
Reviewed study record
Healthy-volunteer pharmacokinetics and hormone response
Design
An escalating-exposure study modeled drug concentrations and growth hormone responses.2
Population
The report describes eight healthy men at each of five exposure levels.2
Outcomes reported
The study observed an episode of growth hormone release and substantial between-person variability in pharmacodynamic responses.2
Limitations
The endpoints were pharmacology and hormone measurements, not clinical benefits. The abstract does not provide enough adverse-event detail for a safety conclusion.2
Reviewed study record
Analytical study after nasal exposure
Design
An analytical study examined urine collected over two days after administration of several growth-hormone-releasing peptides.3
Population
The report states that each compound was administered to one volunteer.3
Outcomes reported
The study identified ipamorelin and metabolites in urine using mass spectrometry.3
Limitations
This establishes an analytical human-exposure report, not evidence of therapeutic efficacy or adequately assessed safety. Results for the other compounds cannot be transferred to ipamorelin.3
Reviewed study record
Receptor assay using excretion-study samples
Design
Researchers tested receptor binding of peptides and metabolites and applied the assay to urine from nasal-administration studies.4
Population
The abstract does not state the participant count or establish whether these samples overlap the earlier analytical report.4
Outcomes reported
The assay detected receptor-binding activity in excreted urine from studies that included ipamorelin.4
Limitations
Receptor binding in a sample is not a patient health outcome. Cohort overlap remains unresolved, so this report should not be counted as independent clinical replication.4
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1007/s00384-014-2030-8. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1023/a:1018955126402. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1002/dta.1787. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1002/dta.1947. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗